Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world setting.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznanie jednej z czterech chorób: makroglobulinemia Waldenströma, przewlekła białaczka limfocytowa, chłoniak strefy brzegowej lub chłoniak pęcherzykowy
- •Wiek co najmniej 18 lat
- •Leczenie lekiem zanubrutinib zgodnie z zatwierdzonym schematem
- •Dla chłoniaka pęcherzykowego: zanubrutinib łącznie z lekiem obinutuzumab
- •Decyzja o leczeniu podjęta przed włączeniem do badania
- •Podpisana zgoda na udział w badaniu
✗ Disqualifies
- •Przeciwwskazania do stosowania zanubrutiniba zgodnie z informacją o leku
- •Jednoczesny udział w innym badaniu klinicznym z lekami badawczymi
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Universitätsklinikum Salzburg, Klinik für Innere Medizin III
Salzburg, Austria
Lübecker Onkologische Schwerpunktpraxis
Lübeck, Germany
Trial contact
Daniel Kummer, Dr.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.